Atossa Therapeutics Stock Price, News & Analysis (NASDAQ:ATOS) $0.75 +0.02 (+2.73%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.72▼$0.7750-Day Range$0.63▼$0.8152-Week Range$0.50▼$1.39Volume191,714 shsAverage Volume274,561 shsMarket Capitalization$94.38 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Atossa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside563.8% Upside$5.00 Price TargetShort InterestBearish5.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.24) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector725th out of 932 stocksPharmaceutical Preparations Industry344th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Atossa Therapeutics has a forecasted upside of 563.8% from its current price of $0.75.Amount of Analyst CoverageAtossa Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.08% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in Atossa Therapeutics has recently decreased by 4.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATOS. Previous Next 3.0 News and Social Media Coverage News SentimentAtossa Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atossa Therapeutics this week, compared to 1 article on an average week.Search Interest9 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows9 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.24) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Atossa Therapeutics Stock (NASDAQ:ATOS)Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More ATOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATOS Stock News HeadlinesDecember 8, 2023 | finance.yahoo.comIs Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?December 4, 2023 | proactiveinvestors.comAtossa Therapeutics taps Arezoo Mirad for Senior Medical DirectorDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 4, 2023 | finance.yahoo.comAtossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorNovember 20, 2023 | finance.yahoo.comAtossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialNovember 13, 2023 | msn.comAtossa Therapeutics GAAP EPS of -$0.05 beats by $0.02November 13, 2023 | proactiveinvestors.comAtossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3QNovember 13, 2023 | finance.yahoo.comAtossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 30, 2023 | proactiveinvestors.comAtossa Therapeutics’ (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situOctober 17, 2023 | finance.yahoo.comCognito Therapeutics Appoints Greg Weaver as Chief Financial OfficerOctober 11, 2023 | bizjournals.comAtossa Therapeutics names finance lead after CFO's quick exitOctober 11, 2023 | finance.yahoo.comFast-food consumption by adolescent girls may sow the seeds of breast cancer decades laterSeptember 18, 2023 | finance.yahoo.comAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023September 18, 2023 | finance.yahoo.comApproximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And TreatmentSeptember 8, 2023 | msn.comCantor Fitzgerald Initiates Coverage of Atossa Therapeutics (ATOS) with Overweight RecommendationSeptember 8, 2023 | msn.comAtossa stock jumps 16% in wake of Cantor overweight ratingSeptember 8, 2023 | markets.businessinsider.comBreast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: AnalystAugust 31, 2023 | msn.comAtossa Therapeutics: Betting Big On Transforming Old Breast Cancer CareAugust 31, 2023 | msn.comAtossa Therapeutics (ATOS) Price Target Increased by 13.51% to 5.36August 23, 2023 | proactiveinvestors.comAtossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral EndoxifenAugust 23, 2023 | finance.yahoo.comAtossa Therapeutics backing Endoxifen in the fight against breast cancerAugust 23, 2023 | proactiveinvestors.comAtossa Therapeutics backing Endoxifen in the fight against...Atossa Therapeutics backing Endoxifen in the fight against breast...August 15, 2023 | finance.yahoo.comQ2 2023 Atossa Therapeutics Inc Earnings CallAugust 14, 2023 | finance.yahoo.comAtossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 20, 2023 | msn.comAtossa gains as Canada greenlights breast cancer trialJuly 20, 2023 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in CanadaSee More Headlines Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees11Year Founded2009Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+563.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.80% Return on Assets-23.82% Debt Debt-to-Equity RatioN/A Current Ratio28.35 Quick Ratio28.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.81Miscellaneous Outstanding Shares125,300,000Free Float115,530,000Market Cap$94.38 million OptionableNot Optionable Beta1.21 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Steven C. Quay FCAP (Age 72)M.D., Ph.D., Chairman, CEO & President Comp: $1.14MMs. Heather Rees (Age 51)SVP, Finance & Principal Accounting Officer Ms. Delly Behen P.H.R.Vice President of Administration & Human ResourcesMr. Eric Van ZantenVice President of Investor & Public RelationsDr. Richard Graydon M.D.Ph.D., Interim Chief Medical OfficerKey CompetitorsCytomX TherapeuticsNASDAQ:CTMXZyVersa TherapeuticsNASDAQ:ZVSAG1 TherapeuticsNASDAQ:GTHXLongboard PharmaceuticalsNASDAQ:LBPHKaryopharm TherapeuticsNASDAQ:KPTIView All CompetitorsInstitutional OwnershipGSA Capital Partners LLPBought 44,788 shares on 11/15/2023Ownership: 0.276%Connor Clark & Lunn Investment Management Ltd.Bought 133,591 shares on 11/13/2023Ownership: 0.106%UBS Group AGBought 33,359 shares on 11/9/2023Ownership: 0.027%Group One Trading L.P.Bought 3,500 shares on 11/9/2023Ownership: 0.000%View All Institutional Transactions ATOS Stock Analysis - Frequently Asked Questions Should I buy or sell Atossa Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATOS shares. View ATOS analyst ratings or view top-rated stocks. What is Atossa Therapeutics' stock price target for 2024? 1 brokerages have issued 1 year price objectives for Atossa Therapeutics' stock. Their ATOS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 563.8% from the stock's current price. View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts. How have ATOS shares performed in 2023? Atossa Therapeutics' stock was trading at $0.5285 at the start of the year. Since then, ATOS shares have increased by 42.5% and is now trading at $0.7532. View the best growth stocks for 2023 here. When is Atossa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ATOS earnings forecast. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter. When did Atossa Therapeutics' stock split? Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO? 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK). Who are Atossa Therapeutics' major shareholders? Atossa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.28%), Connor Clark & Lunn Investment Management Ltd. (0.11%), UBS Group AG (0.03%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ATOS) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.